DGAP-Ad hoc: STADA Arzneimittel

DGAP-Adhoc: STADA Arzneimittel AG: Significant renewal of Supervisory Board brought forward by two years - Annual General Meeting 2016 postponed to August 26, 2016

STADA Arzneimittel AG / Key word(s): Miscellaneous

22.05.2016 15:13

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Bad Vilbel, May 22, 2016 - The Supervisory Board of STADA Arzneimittel AG resolved today to bring forward by two years the originally planned election for 2018 of at least three shareholder representatives. The term of office of the new shareholder representatives shall be five years. The purpose of this realignment of the Supervisory Board is to further strengthen STADA's successful international growth strategy for generics and OTC products.

The candidates, who will be proposed for election at the Annual General Meeting 2016, will be identified by a nomination committee of the Supervisory Board with the support of external advisors and nominated by the Supervisory Board. The nomination committee will be chaired by Dieter Koch. In order to find the best-possible candidates for STADA, a structured selection process has been put in place including a set of criteria that includes professional expertise, personal qualification and independence while taking into account the recommendations in various codes and rules of good corporate governance.

The Executive Board has decided to postpone the Annual General Meeting originally scheduled for June 9, 2016 to August 26, 2016 in order to ensure an orderly and transparent process for the selection of candidates and for the preparation of the election of the new Supervisory Board members. Although the postponement implies that the announcements made in the Federal Gazette of April 28 and May 17, 2016 concerning the Annual General Meeting agenda no longer apply, the Executive Board and Supervisory Board nevertheless expect at the present time that - with the exception of the nomination proposals for the Supervisory Board elections - the previously published agenda will remain unchanged for the rescheduled Annual General Meeting.

Additional information for analysts: STADA Arzneimittel AG / Investor Relations / Stadastraße 2-18 / 61118 Bad Vilbel - Germany / Tel.: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / E-mail: ir@stada.de

Additional information for journalists: STADA Arzneimittel AG / Media Relations / Stadastraße 2-18 / 61118 Bad Vilbel - Germany / Tel.: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail: press@stada.de

Or visit us in the Internet at www.stada.com.

22.05.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap.de

--------------------------------------------------------------------------- Language: English Company: STADA Arzneimittel AG Stadastraße 2-18 61118 Bad Vilbel Germany Phone: +49 (0)6101 603- 113 Fax: +49 (0)6101 603- 506 E-mail: communications@stada.de Internet: www.stada.de ISIN: DE0007251803, DE0007251845, WKN: 725180, 725184, Indices: MDAX Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart; Terminbörse EUREX End of Announcement DGAP News-Service ---------------------------------------------------------------------------